|
Volumn 29, Issue 5, 2002, Pages 890-895
|
Treatment with the angiogenesis inhibitor endostatin: A novel therapy in rheumatoid arthritis
a a a a a a a a |
Author keywords
Angiogenesis; Apoptosis; Endostatin; Rheumatoid arthritis; SCID HuRAg mouse; Treatment
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
COLLAGEN TYPE 4;
ENDOSTATIN;
PHOSPHATE;
SODIUM CHLORIDE;
VON WILLEBRAND FACTOR;
ANGIOGENESIS;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANIMAL TISSUE;
APOPTOSIS;
ARTICLE;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFECT;
DRUG MECHANISM;
HISTOPATHOLOGY;
HUMAN;
HUMAN TISSUE;
LEUKOCYTE COUNT;
MALE;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN DETERMINATION;
RHEUMATOID ARTHRITIS;
SCID MOUSE;
SYNOVIUM;
TISSUE GRAFT;
ANGIOGENESIS INHIBITORS;
ANIMALS;
APOPTOSIS;
ARTHRITIS, RHEUMATOID;
COLLAGEN;
COLLAGEN TYPE XVIII;
DISEASE MODELS, ANIMAL;
ENDOSTATINS;
HUMANS;
MALE;
MICE;
MICE, SCID;
MICROCIRCULATION;
NEOVASCULARIZATION, PATHOLOGIC;
PEPTIDE FRAGMENTS;
SYNOVIAL MEMBRANE;
|
EID: 0036257310
PISSN: 0315162X
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (63)
|
References (17)
|